Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Short term Debt (2016 - 2025)

Integra Lifesciences Holdings' Short term Debt history spans 15 years, with the latest figure at $38.8 million for Q3 2025.

  • For Q3 2025, Short term Debt fell 93.23% year-over-year to $38.8 million; the TTM value through Sep 2025 reached $38.8 million, down 93.23%, while the annual FY2024 figure was $573.2 million, 3844.46% up from the prior year.
  • Short term Debt for Q3 2025 was $38.8 million at Integra Lifesciences Holdings, down from $574.6 million in the prior quarter.
  • Across five years, Short term Debt topped out at $574.6 million in Q2 2025 and bottomed at $4.8 million in Q2 2023.
  • The 5-year median for Short term Debt is $45.0 million (2021), against an average of $124.5 million.
  • The largest annual shift saw Short term Debt surged 5809.38% in 2024 before it crashed 93.23% in 2025.
  • A 5-year view of Short term Debt shows it stood at $45.0 million in 2021, then fell by 15.28% to $38.1 million in 2022, then crashed by 61.89% to $14.5 million in 2023, then soared by 3844.46% to $573.2 million in 2024, then plummeted by 93.24% to $38.8 million in 2025.
  • Per Business Quant, the three most recent readings for IART's Short term Debt are $38.8 million (Q3 2025), $574.6 million (Q2 2025), and $38.8 million (Q1 2025).